主要文件

查看所有文档

SML2956

Nalmefene Hydrochloride

Name: Nalmefene Hydrochloride
Brand: SIGMA

≥98% (HPLC), μ-opioid receptor agonist, powder

别名:

(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylene-morphinan-3,14-diol hydrochloride, NIH 1036, Nalmefene HCl

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₁H₂₅NO₃·HCl

化学文摘社编号:

58895-64-0

分子量:

375.89

NACRES:

NA.77

UNSPSC Code:

12352200

MDL number:

MFCD27937056

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

Nalmefene Hydrochloride, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C=C1CC[C@@]2(O)[C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]1OC5=C(C=C4)O.Cl

InChI

1S/C21H25NO3.ClH/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13;/h4-5,13,16,19,23-24H,1-3,6-11H2;1H/t16-,19+,20+,21-;/m1./s1

InChI key

GYWMRGWFQPSQLK-OPHZJPRHSA-N

说明

Biochem/physiol Actions

Nalmefene hydrochloride, a naltrexone analogue, is an inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor. Nalmefene hydrochloride is used as treatment for addiction.

naltrexone analogue; inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor

pictograms

GHS06,GHS09

signalword

Danger

hcodes

H301,H336,H410

pcodes

P261 - P264 - P270 - P271 - P273 - P301 + P310

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 1 - STOT SE 3

target_organs

Central nervous system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Mild Effect of Nalmefene on Alcoholic Cue-Induced Response Invigoration in Alcohol Use Disorder Without Accompanying Changes in Electrophysiological Signatures of Early Visual Processing and Executive Control.

Bernadett I Gál et al.

Frontiers in pharmacology, 10, 1087-1087 (2019-10-16)

Nalmefene is approved for as-needed pharmacological treatment in alcohol use disorder (AUD) by the European Medicines Agency. While the cellular effects of nalmefene have been thoroughly investigated, data are very limited on how this agent influences neural signals associated with

Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.

Karl Mann et al.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 26(12), 1941-1949 (2016-11-16)

Nalmefene, a mu- and delta-opioid receptor (MOR, DOR) antagonist and a partial kappa-opioid receptor (KOR) agonist, is approved in the European Union and other countries for the reduction of alcohol consumption in alcohol dependent patients with a high drinking risk

Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.

Javier Calleja-Conde et al.

British journal of pharmacology, 173(16), 2490-2505 (2016-05-31)

The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with cocaine. Using operant alcohol self-administration

全球贸易项目编号

货号	GTIN
SML2956-50MG	04065265102346
SML2956-10MG	04065265102339